中国临床药理学杂志2023，Vol.39Issue(23)：3361-3364,4.DOI:10.13699/j.cnki.1001-6821.2023.23.004
人干扰素α2b联合特布他林治疗嗜酸粒细胞性支气管炎患儿的临床研究
Clinical trial of human interferon α2b combined with terbutaline in the treatment of children with eosinophilic bronchitis
摘要
Abstract
Objective To observe the clinical efficacy and safety of recombinant human interferon α2b combined with terbutaline atomization in the treatment of children with eosinophilic bronchitis(EB).Methods The children with EB were randomly divided into control and treatment groups.Control group was given terbutaline 2.5 mg aerosol inhalation therapy,tid.On the basis of control group,treatment group was combined with atomized human interferon α2b 1 mL each time,twice a day.Two groups were treated for 7 days.The clinical efficacy,lung function,inflammatory factors,airway remodeling indexes and adverse drug reactions were compared between two groups.Results In the treatment group,80 cases were enrolled,2 cases dropped off,and 78 cases were included in the analysis.In the control group,81 cases were enrolled,4 cases dropped off,and 77 cases were included in the analysis.After treatment,the total effective rates of treatment and control groups were 97.44％(76 cases/78 cases)and 88.31％(68 cases/77 cases)with significant difference(P＜0.05).After treatment,peak-time ratios of treatment and control groups was(28.24±3.12)％and(25.86±3.03)％,peak-volume ratios was(27.53±2.87)％and(24.76±2.96)％,eosinophil cationic protein levels were(9.76±1.58)and(12.13±2.01)mg·L-1,interleukin-5 levels were(1.42±0.25)and(1.75±0.31)μg·L-1,eosinophils levels were(0.19±0.03)×109 and(0.23±0.04)×109·L-1,human chondroglycoprotein-39 levels were(41.23±6.48)and(49.71±8.25)μg·L-1,connective tissue growth factor levels were(351.06±32.17)and(389.28±37.23)ng·L-1,transforming growth factor-β1 levels were(58.59±6.51)and(64.59±8.14)μg·L-1,and the differences were statistically significant(all P＜0.05).The adverse drug reactions of two groups were mainly vomiting and diarrhea.The total incidences of adverse drug reactions in treatment and control groups were 3.85％and 2.60％,without significant difference(P＞0.05).Conclusion Human interferon α2b injection combined with terbutaline sulfate aerosol inhalation solution has a definitive clinical efficacy in the treatment of EB children,which can significantly improve the pulmonary function of children,inhibit inflammatory response,improve airway remodeling,with good safety.关键词
注射用人干扰素α2b/硫酸特布他林雾化吸入用溶液/嗜酸粒细胞性支气管炎/肺功能/临床疗效/安全性评价Key words
human interferon α2b injection/terbutaline sulfate atomizing solution for inhalation/eosinophilic bronchitis/lung function/clinical effect/safety evaluation分类
医药卫生引用本文复制引用
方辉,刘梦莹,郑武田..人干扰素α2b联合特布他林治疗嗜酸粒细胞性支气管炎患儿的临床研究[J].中国临床药理学杂志,2023,39(23):3361-3364,4.基金项目
安徽省科技攻关计划基金资助项目(AKJ201975212) （AKJ201975212）
